wileyonlinelibrary.com/journal/cas
| INTRODUC TI ON
Nanoparticle-based drug delivery platforms have been developed as suitable vehicles for overcoming pharmacokinetic limitations of chemotherapeutic drug delivery and imaging. Many types of particles have been generated for the distribution of anticancer drugs to tumor tissues. With respect to drug distribution and penetration in tumor tissues, the composition or architecture of nanoparticles must be considered. Metal nanoparticles have been used in a wide range of biomedical applications, such as labeling and probing. 1, 2 However, their in vivo application is often limited because of weak colloidal stability and poor endocytosis. In this regard, the improvement of biocompatible organic materials has been explored. Liposomes have been of particular focus because their lipid bilayer can enhance the colloidal stability and efficacy of intracellular delivery in vivo. Liposomes combined with anticancer drugs have been used to penetrate tumor tissue efficiently. 3 The incorporation of antigen proteins into nanoparticles allows the transfer of biological properties to liposomes. 4 To generate an effective vaccine to enhance immunity, not only materials but also methods of manufacturing must be considered: antigen type and dose; immunostimulatory adjuvant; formulation refinement; and the size, surface charge (anionic, cationic, or neutral), lamellarity, and homogeneity. 5 Several factors to generate an immune response through antigen-carrying nanoparticles must be compared. [6] [7] [8] [9] For example, nanoparticle size-nanoscale or microscale-is likely an important aspect of delivery and thus has been examined by many groups. The relevance of nanoparticle size to the adjuvant activity has been controversial. [10] [11] [12] [13] [14] [15] It was reported that s.c. administration
Recent immunotherapies have shown clinical success. In particular, vaccines based on particulate antigen (Ag) are expected to be implemented based on their efficacy.
In the current study, we describe a strategy entailing Ag-encapsulating PEG-modified liposomes (PGL-Ag) as antigen protein delivery devices and show that the success of the liposome depends on the antigen-presenting cell (APC) capacity; after administration of PGL-Ag, dendritic cells (DCs) in particular take up the Ag and subsequently
prime T cells. For the generation of antitumor T cell responses in the lymphoid tis-
sues, the function of encapsulated Ag-capturing DCs in vivo could be a biomarker.
We next designed a prime-boost strategy to enhance the antitumor effects of the PGL-Ag. In the tumor sites, we show that Ag retention in nanoparticle-capturing DCs promotes a robust antitumor response. Thus, this efficient particulate Ag-based host antigen-presenting cell delivery strategy provides a bridge between innate and adaptive immune response and offers a novel therapeutic option against tumor cells.
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adaptive immunity, dendritic cell, immunotherapy, nanoparticle, tumor microenvironment F I G U R E 1 Dendritic cell (DC) uptake of antigen-encapsulating liposomes in a size-dependent manner. A, Ovalbumin (OVA) antigenencapsulating liposomes-large (1000 nm) and small (200 nm)-were fabricated to contain OVA protein and present rhodamine on the surface. B, The amounts of OVA protein in both liposomes were measured by ELISA (n = 8). C-E, Bone marrow-derived DCs (BM-DCs) were cultured with the two sizes of OVA antigen-encapsulating liposomes for 18 hours (n = 4). Expression of MHC class II on DCs was analyzed by flow cytometry. C, The frequency (E, upper) and mean fluorescent intensity (MFI) (E, lower) of liposome uptake by DCs were measured by FACS at the indicated time points. Significance of difference between 200-nm and 1000-nm liposomes: *P < .05, **P < .01, ***P < .001, Student's t test F I G U R E 2 Macrophage uptake of antigen-encapsulating liposomes. A-C, Bone marrow-derived macrophages (BM-Mϕs) were verified to express CD11b + F4/80 + (A,B-i) and were cultured with two types of ovalbumin (OVA) antigen-encapsulating liposomes, small and large, for 18 hours (n = 4). The frequency (B,C-i) and mean fluorescent intensity (MFI) (C-ii) of BM-Mϕs uptake of the liposomes were measured by flow cytometry at the indicated time points. Significance of difference between 200-nm and 1000-nm liposomes: *P < .05, **P < .01, ***P < .001, Student's t test of 200-nm antigen-entrapped liposomes was effective in the generation of antitumor T cells. 16 However, this treatment did not result in therapeutic effects. 16 Another group showed that a vaccine contain- In the current study, we evaluated an antitumor vaccine composed of large PEG-coated, antigen-encapsulating neutral liposomes (PGL-Ag) and present critical facets of immunotherapy.
| MATERIAL S AND ME THODS

| Mice and cell line
EG7 (OVA-expressing EL4) lymphoma cell line was purchased from ATCC (Manassas, VA, USA). C57BL/6J mice were purchased from CLEA Japan (Tokyo, Japan). CD11c-YFP transgenic mice were purchased from Jackson Laboratories (Bar Harbor, ME, USA 
| Fluorescence-activated cell sorter staining
The following reagents and mAbs specific to mouse proteins were used in these analyses: CD8-FITC (53-6. Fisher Scientific, BD Biosciences (Franklin Lakes, NJ, USA), and MBL (Nagoya, Japan). Cytokine expression by CD8 + T cells was determined using a previously reported protocol for intracellular cytokine staining. 22 Briefly, splenic cells were incubated in the presence of Golgi Plug (BD Biosciences) for 6 hours with or without OVA peptide 257-264 followed by incubation with Abs to surface markers.
The cells were then permeabilized in Cytofix-Cytoperm Plus (BD Biosciences) and stained with a γ-interferon (IFN-γ) mAb. Flow cytometry was carried out using a FACSCalibur or FACSCanto II (BD Biosciences) with FlowJo software (FlowJo, Ashland, OR, USA).
Additional materials and methods can be found in Data S1.
| RE SULTS
| Antigen encapsulated in different types of PGL-Ag captured by different types of APCs in vitro
We generated small and large liposomes and assessed their size distribution and polydispersity index (PDI) as well as fluorescence intensity. According to the measurements obtained by dynamic light scattering, the small and large liposomes were 169 nm and 1029 nm, respectively ( Figure S1 ). Furthermore, the PDI of the small and large liposomes was 0.083 and 0.322, respectively. Because PDI < 0.1
indicates monodispersity, we determined that the small liposomes were monodispersed and the large liposomes were polydispersed.
We also confirmed the formation of liposomes by assessing the lipid composition with transmission electron microscopy ( Figure   S1 ). Next, we analyzed the phospholipid concentration using the Phospholipid Quantitative Determination Kit (PHOSPHOLIPIDS C AUTOKIT 2-10 DEGC 120TST, Wako, Japan), which revealed that the small and large liposomes contained 0.79 and 0.88 mg/mL phospholipids, respectively ( Figure S1D ). In addition, the rhodamine concentration of each liposome dispersion was determined by measurement of absorbance at 570 nm. As shown in Figure S1C ,D, the rhodamine concentrations of the small and large liposomes were Thus, BM-Mϕs captured both types of PGL-Ag, whereas DCs predominantly took up large PGL-Ag. With regard to the amounts of PGL-Ag contained in APCs, the amount of large PGL-Ag was much higher than that of small PGL-Ag.
| Alteration of APC function by capture of PGL-Ag
We speculated that APCs sometimes change after the uptake of exog- :C) ). Seven days after immunization, OVA-specific CD8 + T cells were analyzed using CD8-FITC and OVA tetramer-PE in the spleen, lymph node (LN), liver, and lung. The numbers indicate OVA-H-2K b tetramer + T cells in CD8 T cells. Data were pooled from 8-10 (negative control), 8-9 (200 nm), or 10-11 (1000 nm) independent experiments. *P < .05, **P < .01, ***P < .001, Student's t test. C,D, Same as (A), but antigenspecific T cell responses to small or large OVA-encapsulating liposomes were assessed for γ-interferon (IFN-γ) production by intracellular staining. For this, spleen cells were cultured in the presence and absence of OVA peptide for 6 hours. Numbers indicate the OVA peptidespecific IFN-γ production in CD8 T cells. Data were pooled from 8-10 (negative control), 8-9 (200 nm), or 10-11 (1000 nm) independent experiments. *P < .05, **P < .01, ***P < .001, Student's t test. E, Scheme of antitumor prophylactic model protocol is shown. C57BL/6 mice were injected i.v. with small or large OVA-encapsulating liposomes together with poly(I:C). One week later, the mice were inoculated with EG7 cells s.c. in the right flank. Data were pooled from 5 independent experiments (n = 12). Significance of difference between vehicle and 200-nm or 1000-nm liposomes: *P < .05, **P <0.01, ***P < .001. Significance of difference between 200-nm and 1000-nm liposomes: # P < .05, ## P < .01, ### P < .001, Student's t test Figure 4A,B) . We speculated that small PGL-Ag would be taken up by the APCs. As small PGL-Ag, that is, the anticancer drug within the nanoparticles, are likely to permeate blood vessels, they were reported to have effective antitumor ability. 23 However, small PGL-Ag were captured at equal proportions by all types of APCs, but at low frequency (5%-8%) ( Figure 4C ). In contrast, large PGL-Ag were surprisingly captured at higher amounts in vivo by APCs, particularly by 
) (B)
. Data were pooled from 2 independent experiments (n = 6). C, As a new therapeutic strategy, mice that had been inoculated with 2 × 10 5 EG7 cells were treated twice i.v. with large liposomes and poly(I:C) 6 and 9 days later and were again treated twice i.t. with small or large liposomes and poly(I:C) 12 and 15 days later. Tumor size was measured every 3 days (C, upper panels). Tumor size was measured at every 3 days (C, lower panel). Data were pooled from 4 independent experiments (n = 7). Significance of difference between vehicle and small or large liposomes: *P < .05, **P < .01, ***P < .001. Significance of difference between small and large liposomes: 
| Antigen-presenting activity and antigen-specific T cell induction by Ag-PGL
We assumed that the function of APCs capturing antigen can determine the subsequent antigen-specific T cell response in vivo. As shown in Figure 1B We then investigated whether antigen-specific T cell immunity can be generated in WT mice. C57BL/6 mice were immunized with small or large OVA-encapsulating PGL together with poly(I:C).
Seven days after immunization, OVA-specific CD8 + T cells were analyzed in the spleen, lymph nodes (LNs), liver, and lungs ( Figure 5 ).
Antigen-specific T cell responses to large PGL-Ag were superior to those to small PGL-Ag ( Figure 5A ,B). We also verified that antigen- route. When we administered the large PGL-Ag plus poly(I:C) s.c.,
we did not detect a T cell response as robust as that from i.v. administration ( Figures 5 and S3 ). In addition, the antigen-specific splenic T cell response from i.v. administration was significantly more pronounced than that from s.c. administration (P < .05). We subsequently investigated the vaccine protocol by comparing the form of antigen. Our current approach of administration of large PGL-Ag with poly(I:C) was compared with another vaccine form, that is, large PGL-Ag conjugated with poly(I:C). We found that the T cell responses to both vaccines based on tetramer and antigenspecific IFN-γ production were not statistically different ( Figure   S4A ,B). Therefore, we used the co-administration approach in our experiments thereafter.
| Effective antitumor strategy designed with PGL-Ag vaccine
In the prophylactic tumor models, mice were i. 
| Retention of PGL-Ag by APCs at tumor sites
We next investigated the potential of APCs for capturing PGL-Ag in the tumor sites. We assessed the antigen retention in vivo to elucidate the mechanism of superior antigen-specific T cell immunity that was elicited by boosting with large PGL-Ag. For this analysis, the retention of PGL-Ag in immune cells at tumor sites was monitored with the IVIS instrument, IVIS Lumina Series III, PerkinElmer, Hopkinton, MA, (Figure 7A ,B). Small and large PGL-Ag were retained at the tumor, peaking at 3 hours and gradually decreasing until 24 hours. The large PGL-Ag was sustained at tumor sites for more than 24 hours after administration ( Figure 7A ). When we compared small and large PGL-Ag, the amount and intensity of large PGL-Ag were 2-fold higher than those of small PGL-Ag ( Figure 7B) . Thus, the mechanisms of decreased kinetics of both PGL-Ag were similar, but large PGL-Ag were much more sustained. Then, we assessed the types of APCs that recruit and capture the PGL-Ag and sustain them at the tumor site. In fact, CD103 + and CD103 − DC subsets and F4/80 + Mϕs took up large PGL-Ag 2-3 times more efficiently than small PGL-Ag ( Figure 7C-E) .
Above all, CD103 + DCs and Mϕs showed efficient uptake. Taken together, large PGL-Ag can be taken up by CD103 + DCs or Mϕs at the tumor site more efficiently than small PGL-Ag.
| Dynamics of tumor antigen-specific T cells after treatment with PGL-Ag
To understand the immune response in a successful therapeutic strat- in CTL induction in tumor-bearing or infection models. 19, 25 It is generally known that DCs-but not Mϕs-are specialized for antigen presentation as well as cross-presentation. This might be because lysosomal acidification is prevented in DCs, in which the recruitment of NADPH oxidase II to the early phagosomes increases the pH. 26 Furthermore, the transition of encapsulated antigens from an early endosome/lysosome to cytosol can enhance the cross-presentation. Simultaneously, cathepsins in DCs inhibit proteolytic destruction of antigens. 27, 28 However, the DC subsets that take up and process liposomes have not been fully determined, especially at tumor sites. We found that CD8α + DCs in the spleen and CD103 + DCs in tumor sites specifically endocytosed large PGL-Ag. In addition, we detected vacuoles in DCs that harbored discrete nanoparticles through solution cross-linking of protein; the PGL-Ag remained ( Figure 3B ), and antigen was simultaneously retained and released stably from the particle in both lymphoid organs and tumor sites. These biological findings related to DCs in nanoparticle-treated mice could help improve anticancer immunotherapy.
Although we used only the PGL-Ag for vaccination, we assert the importance of a preclinical approach, that is, priming and boosting 
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